JNJ - Emergent Biosolutions granted FDA clearance for two more COVID-19 vaccine batches

The FDA has greenlighted two additional COVID-19 vaccine batches manufactured by Emergent Biosolutions (NYSE:EBS) for Johnson & Johnson (NYSE:JNJ). The regulator has determined that the batches were safe for use following a thorough review and considering the requirements during the current public health emergency. After a manufacturing mix-up at Emergent’s (EBS) production plant in Baltimore made over 15M doses of J&J COVID-19 vaccine useless, the regulator halted the operations at the plant. To date, the federal agency has cleared eleven batches of J&J (JNJ) COVID-19 vaccines developed at the production site. However, the plant is yet to be included as an authorized manufacturing facility for the vaccine. Emergent (EBS) shares have added ~2.3% in the post-market after falling more than a third during the day in reaction to the loss of a manufacturing contract with the U.S. government.

For further details see:

Emergent Biosolutions granted FDA clearance for two more COVID-19 vaccine batches